Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof

A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is Ra;
• and Y is N;
• or R1 is R4;
• and Y is C—Ra;
• Ra is —CH2NRs-L2-Rb, or —C(═O)NR8-L2-Rb;
• L2 is absent, -(unsubstituted or substituted C1-C6 alkylene)-, -(unsubstituted or substituted C1-C6 alkylene)-N(R9)—, -(unsubstituted or substituted C1-C6 alkylene)q-(unsubstituted or substituted C3-C6cycloalkyl), -(unsubstituted or substituted C1-C6 alkylene)q-(unsubstituted or substituted aryl), -(unsubstituted or substituted C1-C6 alkylene)q-(unsubstituted or substituted C2-C6heterocycloalkyl), or -(unsubstituted or substituted C1-C6 alkylene)q-(unsubstituted or substituted heteroaryl);
• q is 0 or 1;
• Rb is -L3-Q;
• L3 is a linker;
• Q is a chelating moiety or a radionuclide complex thereof;
• L1 is absent or —C(═O)—;
• R2 is ring that is selected from the group consisting of:
• C3-C8cycloalkyl, C2-C8heterocycloalkyl, aryl, or heteroaryl, wherein R2 is unsubstituted or is substituted with R3a, R3b, or R3c, or combinations thereof,
• each R3a, R3b, R3c, R4, and R5 is independently hydrogen, halogen, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C1-C4alkenyl, substituted or unsubstituted C1-C4alkynyl, substituted or unsubstituted C1-C4fluoroalkyl, substituted or unsubstituted C1-C4heteroalkyl, —CN, —N(R9)2, or —OR9;
• R6 is C1-C4alkyl;
• R7 is hydrogen or C1-C4alkyl;
• R8 is hydrogen or C1-C4alkyl;
• each R9 is independently hydrogen, C1-C4alkyl, C1-C4fluoroalkyl, substituted or unsubstituted C1-C4heteroalkyl;
• X1 is CR5 or N;
• X2 is CR4 or N;
• m is 0, 1, or 2;
• and n is 0, 1, 2, or 3.